New Strength Pilates

10/17/2026

10/08/2026

08/28/2026

Osteoboost info!

Curious about the Osteoboost belt?

What it is:
A prescription, FDA-cleared wearable vibration belt worn at the hips and low back. It delivers low-magnitude, high-frequency mechanical vibration, targeting the lumbar spine and hip region specifically. Cleared through the FDA's De Novo pathway in January 2024 as the first non-drug device indicated for osteopenia in postmenopausal women.

Who it's for:
Postmenopausal women with osteopenia (DXA T-score between -1.0 and -2.49). That's the only population studied and the only population it's cleared for. It requires a US prescription.It has not been studied in men, in premenopausal women, or in people with osteoporosis (T-score -2.5 or lower).

What the research showed:
The trial was a 12-month, randomized, sham-controlled study of 126 postmenopausal women ages 52-82, run at the University of Nebraska Medical Center and published in JBMR Plus. Participants either used the active belt or an inactive sham device that only emitted a buzzing sound.

Two things matter here for accuracy:
In the full study group (everyone who started treatment, regardless of how consistently they used it), the primary endpoint, percentage change in vertebral bone strength, was not statistically significant between the active group and sham group.

Among the subgroup who used the belt at least 3 times per week, the results were significant.
This adherent group showed a 0.48% loss of vertebral bone strength versus a 2.84% loss in the sham group. Vertebral bone density loss was also significantly slowed in that group. Loss of vertebral bone density measured by CT scan was 0.29% in the active group versus 1.97% in the sham group.
👉In people who used it consistently, it slowed the rate of bone loss at the spine compared to a sham device. It did not reverse bone loss or build new bone. It slowed the decline. That finding only held up in the subgroup analysis of compliant users. 👈

It has not been shown to reduce fracture risk. The clinical trial did not test whether users have a lower fracture risk, which would have required a much longer study.
It has not been shown to improve strength or balance. No strength or balance outcomes were part of the published trial.

It's a local, site-specific intervention, not a systemic one. This is the core of the pushback from outside researchers.

Bottom line from me: If used to slow bone loss, it should be part of a comprehensive plan with exercise. Don't count on this alone. May be helpful for people who cannot perform meaningful exercise.

08/07/2026

08/02/2026

Friendly reminder.

07/22/2026

✨ REFORMER COURSE Registration is NOW OPEN! ✨

Advance your career with the STOTT PILATES® Intensive Reformer Course—the gold standard in Pilates education.

Designed for aspiring Pilates instructors and movement professionals, this course is ideal for physical therapists, chiropractors, athletic trainers, personal trainers, group fitness instructors, dancers, and movement educators looking to deepen their knowledge and expand their professional skills.

📅 Starts: September 18
⏱️ 50 hours of instruction
📍 4 weekends
🔥 Early Bird pricing ends August 18

06/01/2026

05/29/2026

Great information!

Interdisciplinary symposium on osteoporosis.
Day 1 ✅

05/23/2026

Keep moving!

Walk into your next annual physical. They'll weigh you. They'll measure your height. They'll calculate your BMI. They probably won't measure your waist circumference. The Whitehall II cohort just published 11-year follow-up data demonstrating this is the wrong priority.

The Whitehall II study has followed UK civil servants for over three decades. In this latest analysis (Ben Hassen et al., GeroScience, 2026), researchers tracked 4,593 adults from a baseline age of 65 for a median of 11 years to identify who would lose the ability to perform basic daily activities: dressing, bathing, transferring, walking, toileting, feeding. They wanted to know which midlife test would best identify who would decline.

They tested 10 standard geriatric and fitness measures: walking speed, timed chair rises (how fast you can stand up from a chair five times), balance on one leg, grip strength, lung function (FEV1), BMI, and others. These are the measures geriatricians actually use in practice. They require a clinician, a stopwatch, sometimes a spirometer.

When the researchers ranked all 10 measures by predictive accuracy for 10-year disability, waist circumference came out on top. Higher than walking speed. Higher than grip strength. Higher than balance, chair rises, or lung function. The same pattern held for severe disability, defined as needing help with two or more daily activities.

The team then ran a machine learning analysis to find the smallest combination of measures that would maximize prediction. The final selected set: age, s*x, waist circumference, walking speed, timed chair rises, and balance. For severe disability prediction, walking speed dropped out of the model entirely.

Here's the part that matters for practice. Adding walking speed, chair rises, and balance to waist circumference barely improved the prediction over waist alone. Waist circumference did almost all of the work on its own.

Why does this one measurement carry so much weight? Because waist circumference captures visceral adipose tissue, the metabolically active fat that wraps around your abdominal organs. Subcutaneous fat (the fat under your skin you can pinch) is mostly storage. Visceral fat is a different organ entirely. It secretes inflammatory cytokines including TNF-alpha and interleukin-6 that drive systemic insulin resistance. It promotes ectopic fat deposition in the liver, pancreas, and skeletal muscle. It disrupts adipokine signaling, lowering adiponectin and raising leptin in patterns that accelerate metabolic dysfunction. It correlates with atherosclerosis, type 2 diabetes, dementia, and frailty at higher rates than any other fat depot.

BMI cannot distinguish a person carrying weight as muscle from one carrying it as visceral fat. Two adults with identical BMIs can have radically different metabolic profiles. A 70-year-old man with a BMI of 27 and a 102 cm waist is metabolically a different person from a 70-year-old with the same BMI and an 88 cm waist. The first is at substantially higher cardiometabolic risk despite belonging to the same "weight class." Waist circumference captures part of this difference because it reflects where the fat actually lives.

This is not an argument to skip exercise or to deprioritize functional capacity. Walking speed, grip strength, and balance remain important markers of physical reserve. Training them matters for preserving independence and reducing fall risk. The Whitehall II finding is specifically about screening: when you have to pick one measurement to predict who will decline over the next decade, waist circumference outranked the entire fitness battery in this cohort.

What this looks like in practice. Add waist circumference to your annual physical or your own self-tracking. Measure at the level of your navel, tape parallel to the floor, after exhaling normally. Two minutes including writing it down. Track the trend year over year. A rising waist circumference with stable weight is the signal that body composition is shifting toward visceral fat accumulation, a metabolic warning that BMI will miss entirely.

The most informative aging marker in this 4,593-person cohort was a strip of plastic. The annual physical that skips it is missing the strongest individual predictor of the next decade of independence.

Ben Hassen et al., GeroScience, 2026

Whitehall II cohort, n = 4,593, median 11-year follow-up